Aclidinium Bromide: An Alternative Long-Acting Inhaled Anticholinergic in the Management of Chronic Obstructive Pulmonary Disease (July/August).
CONCLUSIONS:Aclidinium bromide is a novel, inhaled, long-acting anticholinergic that, when administered at the FDA-approved dose, safely produces clinically and statistically significant bronchodilation and improves health status in patients with moderate to severe COPD. Long-term clinical trials assessing the efficacy and safety of aclidinium are warranted.
PMID: 23737515 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Woods JA, Nealy KL, Barrons RW Tags: Ann Pharmacother Source Type: research
More News: Aclidinium Bromide | Bronchitis | Chronic Obstructive Pulmonary | Clinical Trials | Common Cold | Cough | Drugs & Pharmacology | Emphysema | Headache | Migraine | Statistics | Study | Websites